A practical reference on peptide research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-28 and is reviewed periodically as new material appears.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
γ-Butyrolactone (GBL) or gamma-butyrolactone is an organic compound with the formula O=CO(CH2)3. It is a hygroscopic, colorless, water-miscible liquid with a pleasant odor. It is the simplest 4-carbon lactone. It is mainly used as an intermediate in the production of other chemicals, such as N-methyl-2-pyrrolidone. In humans, GBL acts as a prodrug for gamma-hydroxybutyric acid (GHB) and is often used as a recreational drug. GHB acts as a central nervous system (CNS) depressant with effects similar to those of barbiturates.
(2026) describe molars of Helarctos malayanus praemalayanus from the Pleistocene strata of the Tham Hai Cave (Vietnam), and interpret the fossil record from Southeast Asia as indicative of larger body size of Middle Pleistocene sun bears compared to their extant relatives. Probable fossil material of the Asian black bear, representing the first known record of a member of this lineage from northeastern Iberian Peninsula, is described from the Middle Pleistocene strata from Llers Quarry (Spain) by Rufí et al. (2026). Gutiérrez-Carbajal et al. (2026) reconstruct the evolutionary history of cave bears from southwestern Europe on the basis of data from enamel proteomic analysis, recovering Ursus dolinensis as a basal member of the cave bear lineage. Kochnev et al. (2026) study the variation of the size and shape of the hard palate and choanae of Ursus kanivetz and Ursus rossicus, and report possible evidence of a link between the hard palate form and the climate. A study on the ecology of cave bears from Galería 1 inside the Cueva de Guantes (Palencia, Spain) as indicated by isotopic composition of tooth enamel and bone collagen is published by Rodríguez-Franco et al. (2026). Hasegawa et al. (2026) study the distribution of brown bears in the Japanese Archipelago during the Late Pleistocene, reporting remains of exceptionally large individuals from Aomori, Nagano, Shizuoka and Oita. Estraviz-López et al.
== Clinical significance == Myositis may cause thickening of the muscle fascicles. This may be detected with ultrasound scans. Muscle fascicle structure is a useful diagnostic tool for dermatomyositis. Myocytes towards the edges of the muscle fascicle are typically narrower, while those at the centre of the muscle fascicle are a normal thickness. Muscle fascicles may be involved in myokymia, although commonly only individual myocytes are involved.
Sources: en.wikipedia.org
== White Book == The White Book, formally titled Biochemical Nomenclature and Related Documents (1992), contains definitions pertaining to biochemical research, compiled jointly by IUPAC and the International Union of Biochemistry and Molecular Biology.
== Medical uses == Atenolol is used for a number of conditions including hyperthyroidism, hypertension, angina, long QT syndrome, acute myocardial infarction, supraventricular tachycardia, ventricular tachycardia, essential tremor (ET), and the symptoms of alcohol withdrawal. The role for β-blockers in general in hypertension was downgraded in June 2006 in the United Kingdom, and later in the United States, as they are less appropriate than other agents such as ACE inhibitors, calcium channel blockers, thiazide diuretics and angiotensin receptor blockers, particularly in the elderly. Atenolol has been used to treat anxiety disorders, such as generalized anxiety disorder and social anxiety disorder. It is thought that beta blockers do not directly treat psychological symptoms of anxiety, but can help control physical symptoms such as palpitations, and this may interfere with a positive feedback loop to indirectly reduce psychological anxiety. A 2025 systematic review and meta-analysis that included atenolol found widespread prescription of beta blockers for treatment anxiety disorders, but found no evidence of a beneficial effect relative to placebo or benzodiazepines in people with social phobia or panic disorder. However, the quality of evidence, including both numbers of studies and patients as well as quality and risk of bias of those studies, was limited.
Meat can be preserved by salting it, cooking it at or near 100 °C (212 °F) in some kind of fat (such as lard or tallow), and then storing it immersed in the fat. These preparations were popular in Europe before refrigerators became ubiquitous. They are still popular in France, where the term originates. The preparation will keep longer if stored in a cold cellar or buried in cold ground.
Clinicians may improperly connect transgender people's symptoms to their gender transition, a phenomenon known as trans broken arm syndrome. Trans broken arm syndrome is particularly prevalent among mental health practitioners, but exists in all fields of medicine. Misguided investigation of transition-related causes can frustrate patients and cause delay in or refusal of treatment, or misdiagnosis and prescription of a wrong treatment. Misattribution of symptoms to gender-affirming hormone therapy may also cause doctors to erroneously recommend the patient stop taking hormones. Trans broken arm syndrome may also manifest as health insurance companies refusing to pay for treatments, claiming that a mental or physical health problem is inevitable or untreatable due to the patient's transgender status or that a treatment would be too experimental because the patient is transgender. According to The SAGE Encyclopedia of Trans Studies, trans broken arm syndrome is a form of discrimination against transgender people. A 2021 survey by TransActual shows that 57% of transgender people in the United Kingdom put off seeing a doctor when they were ill. In 2014, 43% of transgender counselling clients in the UK said their counsellor "wanted to explore transgender issues in therapy even when this wasn't the reason they had sought help".
Sources: en.wikipedia.org
Porcine All three previously mentioned types of retinol-binding proteins (RBP, CRBP, CRABP) have been identified within the porcine placenta during pregnancy via immunohistochemistry. As previously mentioned, retinol and retinoic acid are modulators of gene expression and are necessary for the proper development and growth of a conceptus. Porcine exhibit a diffuse type placenta that has areolar-gland subunits which allows for transport of larger molecules between dam and fetus. RBP and CRBP have been identified in the endometrial glands and areolar trophoblasts, suggesting that RBP is crucial in transport of retinol from the gland to the trophectoderm of the conceptus. RBP expression has also been identified within the yolk sac, myometrium, oviduct, and numerous other fetal tissues.
Vladimir Khatskelevich Khavinson (Russian: Владимир Хацкелевич Хавинсон; 27 November 1946 – 6 January 2024) was a Russian gerontologist and professor who was Treasurer of the European region of the International Association of Gerontology and Geriatrics; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University in Saint Petersburg; Colonel of medical service (USSR, Russia). Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He was engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions was design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by Khavinson. Patenting endogenous peptides is not a common practice as they are considered a "natural product". He authored 196 patents (Russian and international) as well as of 775 scientific publications.
Benzalkonium chloride – "quat" disinfectant that attacks membranes Bethoxazin – "new broad spectrum industrial microbicide" in 2012, noted as "Canceled in U.S." in 2022 PubChem-EPA query Cybutryne – banned since 2023 in ship paint Dichlone – quinone fungicide/algaecide, not persistent in soil Dichlorophen – also kills invertebrate animals and bacteria Diuron – herbicide/algaecide, inhibits photosynthesis Endothal – herbicide/algaecide, inhibits protein phosphatase 2A Fentin – quinone fungicide/algaecide, discontinued Isoproturon – selective substituted urea herbicide, discontinued Methabenzthiazuron – substituted urea herbicide, discontinued Nabam – fungicide/algicide discontinued in the EU over cancer Oxyfluorfen – herbicide, "very toxic to aquatic life with long lasting effects" Pentachlorophenyl laurate Quinoclamine – herbicide/algicide, not used in most of the EU Quinonamid Simazine – herbicide/algaecide, inhibits photosynthesis Terbutryn Tiodonium
== History == 4-HO-NiPT was first described in the scientific literature, as a metabolite of 4-AcO-DiPT, in 2022. Subsequently, its synthesis was described in 2023 and its pharmacology was reported in 2024. The drug was reported as a possible novel designer drug online in 2022.
Ioxaglic acid (trade name Hexabrix) is pharmaceutical drug used as an iodinated contrast medium for X-ray imaging. It has low osmolality (relatively few molecules per volume), typically resulting in fewer side effects than high-osmolality media. It is manufactured by Guerbet, but marketing in the US has been discontinued. As of 2021, it may still be available in some European countries. It is applied in form of its salts, ioxaglate meglumine and ioxaglate sodium.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.